JSI RESOURCES: Publications

Outcomes and implementation considerations for optimizing dolutegravir-based antiretroviral therapy among PLHIV in northern Uganda


In 2018, the Uganda Ministry of Health (MOH) adopted World Health Organization’s (WHO’s) guidance to switch first-line antiretroviral therapy (ART) from non-nucleoside reverse transcriptase inhibitors (NNRTIs) tom dolutegravir (TLD/DTG). This study conducted by  USAID Regional Health Integration to Enhance Services-North, Lango (RHITES-N, Lango) project and implemented by John Snow, Inc. (JSI), assesses the outcomes and implementation considerations for TLD/DTG optimization to guide policymaking decisions. This abstract was shared at the AIDS 2022 Conference. 

Partner with Us

We strive to build lasting relationships to produce better health outcomes for all.